4:05 PM ET
8-K
Shareholder Meeting
Sunshine Biopharma Shareholder Meeting
The majority shareholder and CEO, Dr. Steve N. Slilaty, approved by written consent several matters related to a public offering that closed on October 9, 2026. These approvals include the issuance of common stock in excess of 20% of outstanding shares at a discount and adjustments to the exercise price and share count of Series D Warrants.